Literature DB >> 10072520

Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells.

M N Avice1, M Sarfati, F Triebel, G Delespesse, C E Demeure.   

Abstract

Lymphocyte activation gene-3 (LAG-3) is an MHC class II ligand structurally and genetically related to CD4. Although its expression is restricted to activated T cells and NK cells, the functions of LAG-3 remain to be elucidated. Here, we report on the expression and function of LAG-3 on proinflammatory bystander T cells that are activated in the absence of TCR engagement. LAG-3 is expressed at high levels on human T cells cocultured with autologous monocytes and IL-2 and synergizes with the low levels of CD40 ligand (CD40L) expressed on these cells to trigger TNF-alpha and IL-12 production by monocytes. Indeed, anti-LAG-3 mAb inhibits both IL-12 and IFN-gamma production in IL-2-stimulated cocultures of T cells and autologous monocytes. Soluble LAG-3Ig fusion protein markedly enhances IL-12 production by monocytes stimulated with infra-optimal concentrations of sCD40L, whereas it directly stimulates monocyte-derived dendritic cells (DC) for the production of TNF-alpha and IL-12, unravelling an enhanced responsiveness to MHC class II engagemenent in DC as compared with activated monocytes. Thus similar to CD40L, LAG-3 may be involved in the proinflammatory activity of cytokine-activated bystander T cells and most importantly it may directly activate DC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072520

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors.

Authors:  Sandrine Buisson; Frédéric Triebel
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

2.  Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates.

Authors:  N Poirier; T Haudebourg; C Brignone; N Dilek; J Hervouet; D Minault; F Coulon; R V de Silly; F Triebel; G Blancho; B Vanhove
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

Review 3.  [T cell-dependent monocyte activation, TNFalpha and apolipoprotein A-I in autoimmunity and inflammation].

Authors:  M Rossol; H Häntzschel; U Wagner
Journal:  Z Rheumatol       Date:  2005-05       Impact factor: 1.372

Review 4.  Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; B K Park
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

Review 5.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 6.  Lag3: From Bench to Bedside.

Authors:  Francesca Aroldi; Reem Saleh; Insiya Jafferji; Carmelia Barreto; Chantal Saberian; Mark R Middleton
Journal:  Cancer Treat Res       Date:  2022

7.  LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses.

Authors:  Kevin D Cook; Jason K Whitmire
Journal:  J Immunol       Date:  2016-05-20       Impact factor: 5.422

8.  CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition.

Authors:  Udai P Singh; Shailesh Singh; Rajesh Singh; Yingzi Cong; Dennis D Taub; James W Lillard
Journal:  J Interferon Cytokine Res       Date:  2008-01       Impact factor: 2.607

9.  Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.

Authors:  Danielle Burger; Nicolas Molnarfi; Martin S Weber; Karim J Brandt; Mahdia Benkhoucha; Lyssia Gruaz; Michel Chofflon; Scott S Zamvil; Patrice H Lalive
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

Review 10.  Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Authors:  Anna Śledzińska; Laurie Menger; Katharina Bergerhoff; Karl S Peggs; Sergio A Quezada
Journal:  Mol Oncol       Date:  2015-10-26       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.